About US
Contact us
-
Takeda's emerging markets cull reaches Russia with $660M Stada selloffAfter Stada CEO Peter Goldschmidtbrushed offthe possibility of a deal for some Takeda drugs in western Europe, the German generics player has laid hands on a differentTakeda portfolio—and it's the la2019/11/6
-
After years-long delay, Novartis' Sandoz finally wins Neulasta biosimilar nodBack in 2016, FDA stiff-armed Novartis and its biosimilar version of Amgen's Neulasta. After three long years and one batch of new study data, the company finally has its approval and and plans to la2019/11/5
-
China approves a new, home-grown Alzheimer's drug—and questions immediately followSince Allergan’s Namenda FDA nod in late 2003, the world hasn’t seen an approved Alzheimer’s disease new drug for 17 years. That drought was brokenSaturday, not by a Western biopharma bigwig, but by2019/11/5
-
Eli Lilly, Boehringer shake up diabetes deal to focus on hot property JardianceEli Lilly and Boehringer Ingelheim have stormed to a market-leading position with their SGLT-2 diabetes drug Jardiance, and they’re pushing that med to the forefront of their longstanding diabetes pa2019/11/4
-
Sanofi pays $315M to settle claims it delayed Lemtrada to avoid investor payoutsSanofi has been battling claims that it dragged its feet on multiple sclerosis (MS) drug candidate Lemtrada, acquired in its Genzyme buyout, to avoid follow-up payments to investors. But now, thedrug2019/11/4
-
FiercePharmaPolitics—Lawmakers, Americans weigh merits of House and Senate pricing billsWelcome to theFiercePharmapolitical roundup, where each Monday we’ll highlight developments in Washington, D.C., and elsewherethat could affect howdrugmakersoperate. As lawmakers continue to debatedr2019/11/1
-
Daiichi Sankyo pulls out of U.S. pain market amid oncology pivot, opioid scrutinyDaiichi Sankyo’s short-lived interest in the U.S. pain management market has officially come to an end, as the company's new CEOcontinues shifting its focus to oncology and the industry reels from th2019/11/1
-
FDA: Zantac carcinogens no more dangerous than 'grilled or smoked meats'Drugmakers may be recalling theheartburn med Zantac around the world, but the FDA wants consumers to stop worrying. Higher-than-recommended levelsof a possiblecarcinogenin the pills are no more dange2019/10/31
-
J&J taps kidney specialist Vifor for Invokana marketing helpJohnson & Johnson scored a one-of-a-kind win for SGLT2 med Invokana in September with an FDA approval to treat kidney disease. Now, as a newcomer to the field, J&J is seeking an experienced h2019/10/31
-
Lilly, BI's Jardiance still beats Novo's Rybelsus when it comes to cost-effectiveness: ICERThe Institute for Clinical and Economic Review (ICER) started giving Novo Nordisk a hard time about the cost-effectiveness of its oral version of semaglutide, Rybelsus, before the drug was even appro2019/10/30